Saul-Wilson Syndrome

Mendelian MONDO:0019407 Pathograph 27 Show in embeddings browser Primordial dwarfism Skeletal dysplasia

Saul-Wilson syndrome is a primordial skeletal dysplasia caused by a single recurrent de novo heterozygous COG4 substitution, p.Gly516Arg. COG4 is a lobe-A subunit of the conserved oligomeric Golgi (COG) complex, which organizes vesicular transport at the Golgi. What makes the disorder mechanistically distinctive is that it is not a loss of COG4: patient fibroblasts have normal COG4 mRNA and protein, and the variant instead shifts the steady-state balance of Golgi traffic - anterograde ER-to-Golgi transport is delayed while retrograde Golgi-to-ER recycling is accelerated. The Golgi shrinks and its stacks collapse. Bulk protein glycosylation is nonetheless largely preserved, and the measurable glycosylation defect is restricted to decorin, a secreted extracellular-matrix proteoglycan - which is why the phenotype is skeletal rather than the multisystem picture of biallelic COG4-CDG, a genuinely different disease in the same gene. Clinically: profound short stature, distinctive craniofacial features, short distal phalanges and often clubfoot, with normal cognition.

Ask OpenScientist

Ask a research question about Saul-Wilson Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
14
Phenotypes
1
Gaps
27
Pathograph
1
Genes
5
Medical Actions
2
Models
7
References
1
Deep Research
🏷

Classifications

Harrison's Part
GENETICS ENVIRONMENT DISEASE
ISDS Skeletal Nosology
primordial dwarfism and slender bones
👪

Inheritance

1
Autosomal dominant, typically de novo HP:0000006
Heterozygous de novo COG4 variants. Offspring of an affected individual have a 50% risk of inheriting the variant.
Autosomal dominant inheritance De novo rate: Typically de novo; sib recurrence has been observed in one family and is attributed to parental germline mosaicism.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"SWS is an autosomal dominant disorder typically caused by a de novo pathogenic variant. Sib recurrence has been observed in one family and is thought to result from germline mosaicism in a parent."
States both the dominant de novo pattern and the single germline-mosaicism recurrence that qualifies it.
?

Discussions and Knowledge Gaps

1
Is altered decorin glycosylation sufficient to produce the Saul-Wilson skeletal phenotype, or is it a marker of a broader extracellular-matrix defect that has not yet been measured?
KNOWLEDGE GAP sws_decorin_sufficiency
Attached to
pathophysiology#Selective Decorin Glycosylation Defect
Decorin is the only protein shown to be abnormally glycosylated in patient cells, and bulk glycosylation is preserved - so it carries the entire explanatory weight between a shrunken Golgi and a skeletal dysplasia. That is a lot to rest on one assay of one proteoglycan, and no reported experiment tests whether correcting or phenocopying the decorin defect changes the skeletal outcome.
⚙

Pathophysiology

7
Recurrent COG4 p.Gly516Arg Substitution
A heterozygous de novo missense change in a lobe-A subunit of the conserved oligomeric Golgi complex. Critically, this is not haploinsufficiency: patient fibroblasts have undiminished COG4 mRNA and protein, so the variant protein is present and acting, not absent.
COG4 hgnc:18620 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves COG4 (hgnc:18620). hgnc:18620 is a gene from the HUGO Gene Nomenclature Committee.
Genetic context allele_type: missense variant_origin: DE_NOVO zygosity: HETEROZYGOUS functional_impact_category: UNKNOWN
A single recurrent heterozygous missense substitution. Its impact is not loss of function - COG4 mRNA and protein levels are preserved - and no published work assigns it to a named functional class, so functional_impact_category is recorded as UNKNOWN rather than guessed at.
Animal models
C. elegans cogc-4(av107) Caenorhabditis elegans fails to recapitulate The same substitution, made endogenously in the orthologous gene, causes nothing detectable in the worm. This is a constraint on how the human variant is understood: whatever it does, it is not a cell-autonomous insult that any COG4-expressing organism would register.
Downstream
Imbalanced Bidirectional Golgi Vesicular Traffic
Show evidence (2 references)
PMID:30290151 SUPPORT In Vitro
"Affected individuals' fibroblasts, whose COG4 mRNA and protein were not decreased"
Rules out reduced COG4 abundance as the mechanism, which is what forces a non-loss-of-function reading of the variant.
PMID:30290151 SUPPORT In Vitro
"The conserved oligomeric Golgi (COG) complex is involved in intracellular vesicular transport, and is composed of eight subunits distributed in two lobes, lobe A (COG1-4) and lobe B (COG5-8)."
Identifies the complex and the lobe in which COG4 sits.
Imbalanced Bidirectional Golgi Vesicular Traffic
Patient fibroblasts show delayed anterograde vesicular trafficking from the ER to the Golgi together with accelerated retrograde recycling from the Golgi back to the ER. The disorder is therefore one of steady-state imbalance in both directions, not a simple block - a distinction that matters because it predicts a shrinking rather than a distended Golgi.
dermal fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves dermal fibroblast, annotated with fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
endoplasmic reticulum to Golgi vesicle-mediated transport GO:0006888 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888). GO:0006888 is a biological process from the Gene Ontology. ↓ DECREASED retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum GO:0006890 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum (GO:0006890). GO:0006890 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Golgi Volume Loss and Stack Collapse
Intermittent neutropenia Granulocyte development and release are secretion-dependent; grouped here as the most plausible route, which has not been investigated in this disorder.
Elevated liver transaminases Hepatocytes are among the most secretory cell types; grouped here, with no established mechanism.
Show evidence (1 reference)
PMID:30290151 SUPPORT In Vitro
"exhibited delayed anterograde vesicular trafficking from the ER to the Golgi and accelerated retrograde vesicular recycling from the Golgi to the ER"
The measured bidirectional trafficking defect in patient cells.
Golgi Volume Loss and Stack Collapse
The altered steady-state equilibrium decreases Golgi volume and collapses the Golgi stacks - the structural consequence of removing more membrane retrogradely than arrives anterogradely.
Golgi organization GO:0007030 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal Golgi organization (GO:0007030). GO:0007030 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Golgi apparatus GO:0005794 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves Golgi apparatus (GO:0005794). GO:0005794 is a cellular component from the Gene Ontology.
Downstream
Selective Decorin Glycosylation Defect
Glypican Accumulation and Elevated wnt4 Signalling
Show evidence (1 reference)
PMID:30290151 SUPPORT In Vitro
"This altered steady-state equilibrium led to a decrease in Golgi volume, as well as morphologic abnormalities with collapse of the Golgi stacks."
Documents both the volume loss and the morphological collapse.
Selective Decorin Glycosylation Defect
Despite a visibly abnormal Golgi, protein glycosylation in patient serum and fibroblasts is not notably altered. The one demonstrated exception is decorin, a proteoglycan secreted into the extracellular matrix, whose Golgi-dependent glycosylation is altered. This selectivity is the reason the disease presents as a skeletal dysplasia rather than as a congenital disorder of glycosylation, and it is also the weakest link in the causal chain: no study has yet shown that altered decorin glycosylation is sufficient to produce the skeletal phenotype.
proteoglycan biosynthetic process GO:0030166 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal proteoglycan biosynthetic process (GO:0030166). GO:0030166 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Profound Short Stature and Skeletal Dysplasia
Lamellar cataracts Decorin and related small leucine-rich proteoglycans are extracellular-matrix components of ocular tissue; grouped here as the most plausible route, which has not been shown directly.
Rod-cone retinal dystrophy Grouped with the other ocular findings as a probable extracellular-matrix consequence; not demonstrated.
Hearing loss Conductive, sensorineural and mixed loss are reported; the conductive component is plausibly skeletal, but no mechanism has been established.
Cystic macular changes Grouped with the other ocular findings as a probable extracellular-matrix consequence; not demonstrated.
Show evidence (1 reference)
PMID:30290151 SUPPORT In Vitro
"protein glycosylation in sera and fibroblasts from affected subjects was not notably altered, but decorin, a proteoglycan secreted into the extracellular matrix, showed altered Golgi-dependent glycosylation"
Establishes both the sparing of bulk glycosylation and the single demonstrated proteoglycan defect.
Glypican Accumulation and Elevated wnt4 Signalling
The proteoglycan defect is not confined to decorin. Patient fibroblasts accumulate glypicans - heparan sulfate proteoglycans that gate several growth and bone-development pathways - and the same accumulation occurs in zebrafish embryos expressing COG4 p.G516R. Downstream, wnt4 transcripts rise selectively, and overexpressing wnt4 alone phenocopies the developmental defects, so the elevated wnt4 is doing causal work rather than marking the lesion. The Wnt inhibitor LGK974 partially corrects body length, which is the strongest evidence in this disorder that a downstream node is pharmacologically addressable.
heparan sulfate proteoglycan metabolic process GO:0030201 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal heparan sulfate proteoglycan metabolic process (GO:0030201). GO:0030201 is a biological process from the Gene Ontology. ⚠ ABNORMAL non-canonical Wnt signaling pathway GO:0035567 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased non-canonical Wnt signaling pathway (GO:0035567). GO:0035567 is a biological process from the Gene Ontology. ↑ INCREASED
Animal models
Zebrafish COG4 p.Gly516Arg expressing embryos Zebrafish recapitulates The mechanism was established in this model, not merely reproduced by it - glypican accumulation, the selective wnt4 increase, the phenocopy on wnt4 overexpression, and the partial pharmacological rescue are all zebrafish results.
Downstream
Impaired Chondrocyte Differentiation and Secretome
Profound Short Stature and Skeletal Dysplasia Convergent-extension defects and shortened body length in the zebrafish model are the developmental route from glypican/wnt4 dysregulation to the growth phenotype.
Show evidence (3 references)
PMID:34595172 SUPPORT In Vitro
"SWS fibroblasts accumulate glypicans, a group of heparan sulfate proteoglycans (HSPGs) critical for growth and bone development through multiple signaling pathways."
Extends the proteoglycan defect from decorin to the glypicans in patient cells.
PMID:34595172 SUPPORT Model Organism
"we assessed wnt levels and found a selective increase of wnt4 transcripts in the presence of COG4 p.G516R"
Identifies the specific signalling change downstream of glypican accumulation.
PMID:34595172 SUPPORT Model Organism
"overexpression of wnt4 mRNA phenocopies these developmental defects"
Phenocopy by wnt4 alone is what makes the elevated wnt4 causal rather than correlative.
Impaired Chondrocyte Differentiation and Secretome
In a chondrocyte-relevant cell type carrying a CRISPR knock-in of the variant, 3D spheroids are smaller and apoptosis is increased - impaired in vitro chondrogenesis. The defect is largely non-cell-autonomous: adding wild-type cells or merely their conditioned medium rescues both cell death and spheroid size, pointing at missing secreted matrix components rather than an intrinsic block. Secretome analysis identifies MMP13 and IGFBP7, both chondro-osteogenic, as selectively under-secreted, and the cells show reduced MMP13 and COL10A1 differentiation markers with a delayed BMP2 response. Notably, bulk N-glycans change only modestly, which reinforces that this is a trafficking and secretion disease rather than a glycosylation disease.
chondrocyte CL:0000138 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves chondrocyte (CL:0000138). CL:0000138 is a cell type from the Cell Ontology.
chondrocyte differentiation GO:0002062 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased chondrocyte differentiation (GO:0002062). GO:0002062 is a biological process from the Gene Ontology. ↓ DECREASED protein secretion GO:0009306 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased protein secretion (GO:0009306). GO:0009306 is a biological process from the Gene Ontology. ↓ DECREASED apoptotic process GO:0006915 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased apoptotic process (GO:0006915). GO:0006915 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Profound Short Stature and Skeletal Dysplasia
Skeletal fragility Under-secretion of chondro-osteogenic matrix components is the plausible route to fragile bone; not demonstrated directly.
Premature degenerative joint disease The adult-onset consequence of the same abnormal cartilage matrix: chondrocytes that differentiate and secrete abnormally produce cartilage that wears out decades early.
Show evidence (4 references)
PMID:36393834 SUPPORT In Vitro
"we found that cells carrying the COG4p.G516R variant made smaller spheroids and had increased apoptosis, indicating impaired in vitro chondrogenesis"
The chondrogenic defect measured in a disease-relevant cell type.
PMID:36393834 SUPPORT In Vitro
"Adding WT cells or their conditioned medium reduced cell death and increased spheroid sizes of COG4p.G516R mutant cells, suggesting a deficiency in secreted matrix components."
Rescue by conditioned medium alone establishes the defect as non-cell-autonomous - a secreted-factor deficiency.
PMID:36393834 SUPPORT In Vitro
"Mass spectrometry-based secretome analysis showed selectively impaired protein secretion, including MMP13 and IGFBP7 which are involved in chondrogenesis and osteogenesis."
Names the specific under-secreted factors linking the Golgi lesion to the cartilage phenotype.
+ 1 more reference
Profound Short Stature and Skeletal Dysplasia
The clinical endpoint: profound short stature with distinctive craniofacial features, short distal phalanges of fingers and toes and often clubfoot, with cognition normal.
Downstream
Profound short stature The growth endpoint of the extracellular-matrix defect.
Short distal phalanges of fingers Acral skeletal expression of the same dysplasia.
Clubfoot Skeletal/positional consequence of the dysplasia.
Distinctive craniofacial features Craniofacial skeletal expression of the dysplasia.
Atlantoaxial instability Cervical skeletal consequence, and the finding that drives the activity restriction; the specific route from altered proteoglycan glycosylation to ligamentous or odontoid instability is not established.
Delayed speech and language development Early speech and motor development are delayed while cognition is normal; grouped with the developmental consequences, with no established mechanism.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"Saul-Wilson syndrome (SWS) is a skeletal dysplasia characterized by profound short stature, distinctive craniofacial features, short distal phalanges of fingers and toes, and often clubfoot."
GeneReviews defines the clinical endpoint.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Saul-Wilson Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

14
Blood 1
Intermittent neutropenia VERY_FREQUENT Decreased total neutrophil count HP:0001875 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intermittent neutropenia, annotated with Decreased total neutrophil count (HP:0001875). HP:0001875 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:31949312 SUPPORT Human Clinical
"Although neutropenia was not appreciated in any person when blood counts were obtained within the first two months of life (n=4), it was noted in all individuals for whom values were available for analysis (n=12)."
Gives the actual denominator - present in 12 of 12 tested beyond the neonatal window - which is what makes this VERY_FREQUENT rather than the abstract's unquantified "frequently observed".
PMID:31949312 SUPPORT Human Clinical
"This neutropenia was intermittent, but did not have any noticeable cyclic periodicity."
The intermittency without periodicity, which is why a single count cannot exclude the finding.
Ear 1
Hearing loss OCCASIONAL Hearing impairment HP:0000365 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hearing loss (conductive, sensorineural or mixed), annotated with Hearing impairment (HP:0000365). HP:0000365 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"Other findings can include hearing loss (conductive, sensorineural, and mixed)"
GeneReviews records hearing loss of all three types among the variable findings.
Eye 2
Lamellar cataracts OCCASIONAL HP:0000518 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Lamellar cataract, annotated with Cataract (HP:0000518). HP:0000518 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"Other findings can include hearing loss (conductive, sensorineural, and mixed), lamellar cataracts, and/or rod-cone retinal dystrophy."
GeneReviews lists lamellar cataract among the variable findings.
Rod-cone retinal dystrophy VERY_FREQUENT Rod-cone dystrophy HP:0000510 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Rod-cone dystrophy (HP:0000510). HP:0000510 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:32078278 SUPPORT Human Clinical
"lamellar cataracts, and/or rod-cone retinal dystrophy"
GeneReviews lists rod-cone retinal dystrophy among the variable findings. PARTIAL because the "and/or" phrasing understates the frequency found on systematic examination.
PMID:31949312 SUPPORT Human Clinical
"Retinal degeneration consistent with a rod-cone dystrophy (retinitis pigmentosa) was present in all four patients who underwent detailed ophthalmic exams at the NIH Clinical Center; it was also reported in several patients whose records were reviewed."
The systematic ophthalmic examination behind the VERY_FREQUENT classification - four of four examined.
Head and Neck 1
Distinctive craniofacial features VERY_FREQUENT Abnormal facial shape HP:0001999 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Distinctive craniofacial appearance, annotated with Abnormal facial shape (HP:0001999). HP:0001999 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"profound short stature, distinctive craniofacial features"
GeneReviews names the facial gestalt among the defining features.
Limbs 1
Clubfoot FREQUENT Talipes equinovarus HP:0001762 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Clubfoot, annotated with Talipes equinovarus (HP:0001762). HP:0001762 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"short distal phalanges of fingers and toes, and often clubfoot"
GeneReviews records clubfoot as often present.
Metabolism 1
Elevated liver transaminases OCCASIONAL Elevated circulating hepatic transaminase concentration HP:0002910 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Elevated circulating hepatic transaminase concentration (HP:0002910). HP:0002910 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31949312 SUPPORT Human Clinical
"Novel findings included elevation of liver transaminases, skeletal fragility, rod-cone dystrophy, and cystic macular changes."
One of the findings newly recognized when the cohort phenotype was defined.
Musculoskeletal 2
Atlantoaxial instability OCCASIONAL HP:0003467 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Atlantoaxial instability (HP:0003467). HP:0003467 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"possible C1-C2 subluxation and/or spinal cord compression"
GeneReviews names C1-C2 subluxation and cord compression among the manifestations to address.
Premature degenerative joint disease OCCASIONAL Premature osteoarthritis HP:0003088 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Premature osteoarthritis (HP:0003088), qualified as young adult onset. HP:0003088 is a phenotype from the Human Phenotype Ontology.
Onset: YOUNG ADULT
Show evidence (1 reference)
PMID:31949312 SUPPORT Human Clinical
"Premature degenerative joint disease was seen in two adults in their 20s, with early joint replacement in one (see supplementary figure S2J)."
The cohort observation, including the age at onset that makes this an adult complication rather than a childhood feature.
Nervous System 1
Delayed speech and language development FREQUENT HP:0000750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"Early development (primarily speech and motor) is delayed; cognition is normal."
GeneReviews records the delay and, in the same sentence, that cognition is spared.
Growth 1
Profound short stature VERY_FREQUENT Severe short stature HP:0003510 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Severe short stature (HP:0003510). HP:0003510 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"a skeletal dysplasia characterized by profound short stature, distinctive craniofacial features"
GeneReviews names profound short stature as the defining feature.
Other 3
Short distal phalanges of fingers VERY_FREQUENT Short distal phalanx of finger HP:0009882 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Short distal phalanx of finger (HP:0009882). HP:0009882 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"short distal phalanges of fingers and toes, and often clubfoot"
GeneReviews lists short distal phalanges among the defining features.
Skeletal fragility OCCASIONAL Increased susceptibility to fractures HP:0002659 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Increased susceptibility to fractures (HP:0002659). HP:0002659 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31949312 SUPPORT Human Clinical
"Novel findings included elevation of liver transaminases, skeletal fragility, rod-cone dystrophy, and cystic macular changes."
Skeletal fragility named among the novel cohort findings.
Cystic macular changes FREQUENT Cystoid macular edema HP:0011505 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cystoid macular changes, annotated with Cystoid macular edema (HP:0011505). HP:0011505 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31949312 SUPPORT Human Clinical
"A pigmentary retinopathy consistent with a rod-cone dystrophy was noted in all four patients, whereas macular cystic changes were documented in two of the four individuals seen at the NIH Clinical Center."
Gives the numerator and denominator for both retinal findings; two of four supports FREQUENT.
🧬

Genetic Associations

1
COG4
Gene: COG4 hgnc:18620 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is COG4 (hgnc:18620). hgnc:18620 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: DE_NOVO
Show evidence (2 references)
PMID:30290151 SUPPORT Human Clinical
"All affected subjects harbored heterozygous de novo variants in COG4, giving rise to the same recurrent amino acid substitution (p.Gly516Arg)."
Establishes the gene and the single recurrent substitution.
PMID:32078278 SUPPORT Human Clinical
"To date only two COG4 variants, both resulting in a p.Gly516Arg missense change, have been reported."
Confirms the allelic restriction at the level of reported variants.
💊

Medical Actions

5
Skeletal Dysplasia and Physiatry Management
Action: orthopedic surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is orthopedic surgical procedure (NCIT:C16186). NCIT:C16186 is a clinical intervention from the NCI Thesaurus. Ontology label: Orthopedic Surgical Procedure NCIT:C16186
Care through a skeletal dysplasia or physiatry clinic - orthopedist, occupational and physical therapy, rehabilitation - covering clubfoot repair, possible C1-C2 subluxation or cord compression, mobility after clubfoot repair, and osteoarticular pain.
Target Phenotypes: Clubfoot HP:0001762 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Clubfoot, annotated with Talipes equinovarus (HP:0001762). HP:0001762 is a phenotype from the Human Phenotype Ontology. Atlantoaxial instability HP:0003467 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Atlantoaxial instability (HP:0003467). HP:0003467 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"Skeletal dysplasia or physiatry clinic (orthopedist, OT & PT, rehabilitation specialist) to address repair of clubfoot"
GeneReviews management recommendation.
Avoidance of Gymnastics and Trampolining
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
An explicit "agents and circumstances to avoid" item: gymnastics and trampoline jumping are contraindicated until atlanto-axial instability has been excluded. This is a safety instruction, not a general activity recommendation, and it is time-limited by the imaging result.
Target Phenotypes: Atlantoaxial instability HP:0003467 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Atlantoaxial instability (HP:0003467). HP:0003467 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"Participation in gymnastics and jumping on a trampoline until atlanto-axial instability is excluded."
The GeneReviews Agents/Circumstances to Avoid entry, quoted directly.
Sensory Surveillance and Treatment
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Standard treatment for cataracts, retinal dystrophy and hearing loss, with routine surveillance for each, alongside monitoring of growth, feeding, development and musculoskeletal status.
Target Phenotypes: Cataract HP:0000518 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Cataract (HP:0000518). HP:0000518 is a phenotype from the Human Phenotype Ontology. Hearing impairment HP:0000365 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hearing impairment (HP:0000365). HP:0000365 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"standard treatment for feeding issues, speech delay, cataracts and retinal dystrophy, and hearing loss"
GeneReviews management recommendation.
Growth Hormone Supplementation (Ineffective)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: somatropin NCIT:C837 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses somatropin (NCIT:C837). NCIT:C837 is a therapeutic agent from the NCI Thesaurus.
Curated as a negative result rather than a recommendation. A retrospective analysis comparing height-for-age model fits before and after starting growth hormone found no apparent effect on height in Saul-Wilson syndrome. That is the expected outcome for a cell-intrinsic secretion and matrix defect, and it matters practically: the same paper warns against unnecessarily aggressive nutritional intervention aimed at a weight target that is not achievable in a genetically determined primordial dwarfism.
Show evidence (1 reference)
PMID:32652690 REFUTE Human Clinical
"we performed statistical comparisons of height-for-age model fits before and after initiation of growth hormone supplementation, and found that this therapy does not appear to influence height in individuals with SWS"
Refutes growth hormone as an effective height intervention in this disorder, which is why the entry records it as a negative result.
Genetic Counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Counseling covers the de novo dominant mechanism, the 50% transmission risk from an affected individual, and the germline-mosaicism recurrence risk that the single reported sib pair implies.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"The risk to offspring of an individual with SWS of inheriting the COG4 pathogenic variant is 50%."
GeneReviews genetic counseling guidance.
🔬

Diagnosis

1
Molecular genetic testing of COG4 (Heterozygous COG4 c.1546G>A p.(Gly516Arg))
Unusually straightforward for a rare disease: every reported patient carries the same de novo heterozygous substitution, so a targeted single variant test confirms the diagnosis. Note that other COG4 variants cause a biallelic congenital disorder of glycosylation with a different phenotype, so the gene name alone is not the answer - the specific allele is.
molecular genetic testing NCIT:C15709 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"The diagnosis of SWS is established in a proband with marked short stature, typical facial and skeletal features, and a heterozygous pathogenic variant in COG4 identified by molecular genetic testing."
The GeneReviews diagnostic criterion.
📊

Prevalence

1
Worldwide
Cases In Literature Not yet documented
Ultra-rare. Fourteen affected individuals were described in the gene-discovery report; GeneReviews counted sixteen reported individuals. No population rate has been published.
Show evidence (1 reference)
PMID:32078278 SUPPORT Human Clinical
"To date, 16 affected individuals have been reported."
GeneReviews gives the reported case count, which is what stands in for a prevalence estimate here.
🐁

Animal Models

2
Zebrafish COG4 p.Gly516Arg expressing embryos
An overexpression rather than a knock-in model, and that is the caveat to carry through everything below - but it reproduces the two things the human disorder needs explaining: short body length and defective cartilage chondrocyte intercalation, both traceable to glypican accumulation and a selective rise in wnt4.
Species
Zebrafish
Genotype
Expression of human COG4 p.Gly516Arg mRNA in wild-type embryos
Publication
PMID:34595172
Pathograph links
Glypican Accumulation and Elevated wnt4 Signalling recapitulates fidelity: moderate The mechanism was established in this model, not merely reproduced by it - glypican accumulation, the selective wnt4 increase, the phenocopy on wnt4 overexpression, and the partial pharmacological rescue are all zebrafish results.
Limitations: Dominant human mRNA expressed in a wild-type background, so the dose is not physiological and a dominant-negative artefact cannot be formally excluded. The LGK974 rescue is also biphasic - correcting at low concentration and worsening at slightly higher - which is what one expects of a pathway that must be tuned rather than switched off, but it makes the rescue a weaker causal argument than a clean dose-response would be.
Readouts
Larval body length under Wnt inhibition
Direction: RESTORED
Interpretation: Partial pharmacological rescue supports Wnt signalling as the effector arm, with the biphasic response as the stated caveat.
Show evidence (1 reference)
PMID:34595172 SUPPORT Model Organism
"LGK974, an inhibitor of Wnt signaling, corrects the shortened body length at low concentrations but amplifies it at slightly higher concentrations."
The rescue and its biphasic limitation, quoted together because they are one result.
Show evidence (1 reference)
PMID:34595172 SUPPORT Model Organism
"These animals show phenotypes consistent with convergent extension (CE) defects during gastrulation, shortened body length, and malformed jaw cartilage chondrocyte intercalation at larval stages."
The developmental phenotype that makes this model informative for the glypican/wnt4 node.
C. elegans cogc-4(av107)
A genuine negative result, and the more rigorous model design of the two: an endogenous knock-in of the orthologous substitution rather than overexpression of the human protein. It produced no detectable phenotype - not on observation, not under heat or Paraquat stress, and not on RNAi against the other seven COG subunits. Recorded because a published negative that took this much work to establish should not have to be rediscovered.
Species
Caenorhabditis elegans
Genotype
cogc-4(av107) - CRISPR-Cas9 knock-in of the orthologous glycine-to-arginine substitution
Publication
PMID:33688625
Pathograph links
Recurrent COG4 p.Gly516Arg Substitution fails to recapitulate fidelity: low The same substitution, made endogenously in the orthologous gene, causes nothing detectable in the worm. This is a constraint on how the human variant is understood: whatever it does, it is not a cell-autonomous insult that any COG4-expressing organism would register.
Limitations: Absence of a phenotype under the assays used is not absence of a molecular defect - the authors say so themselves, and recommend directly assessing Golgi function rather than screening for organismal phenotypes. C. elegans also lacks cartilage and endochondral bone entirely, so the tissue in which the human disease manifests has no counterpart to examine.
Show evidence (2 references)
PMID:33688625 REFUTE Model Organism
"Our data suggest that this mutation in cogc-4(av107) worms does not lead to a detectable phenotype."
The negative conclusion, stated by the authors.
+ 1 more reference
{ }

Source YAML

click to show 
name: Saul-Wilson Syndrome
creation_date: "2026-08-27T01:40:00Z"
category: Mendelian
synonyms:
- SWS
- SWILS
- microcephalic osteodysplastic dysplasia, Saul-Wilson type
description: >-
  Saul-Wilson syndrome is a primordial skeletal dysplasia caused by a single
  recurrent de novo heterozygous COG4 substitution, p.Gly516Arg. COG4 is a
  lobe-A subunit of the conserved oligomeric Golgi (COG) complex, which
  organizes vesicular transport at the Golgi. What makes the disorder
  mechanistically distinctive is that it is not a loss of COG4: patient
  fibroblasts have normal COG4 mRNA and protein, and the variant instead shifts
  the steady-state balance of Golgi traffic - anterograde ER-to-Golgi transport
  is delayed while retrograde Golgi-to-ER recycling is accelerated. The Golgi
  shrinks and its stacks collapse. Bulk protein glycosylation is nonetheless
  largely preserved, and the measurable glycosylation defect is restricted to
  decorin, a secreted extracellular-matrix proteoglycan - which is why the
  phenotype is skeletal rather than the multisystem picture of biallelic
  COG4-CDG, a genuinely different disease in the same gene. Clinically:
  profound short stature, distinctive craniofacial features, short distal
  phalanges and often clubfoot, with normal cognition.
disease_term:
  preferred_term: microcephalic osteodysplastic dysplasia, Saul-Wilson type
  term:
    id: MONDO:0019407
    label: microcephalic osteodysplastic dysplasia, Saul-Wilson type
parents:
- Primordial dwarfism
- Skeletal dysplasia
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
  isds_skeletal_category:
  - classification_value: primordial_dwarfism_and_slender_bones
    notes: >-
      ISDS Nosology of Genetic Skeletal Disorders, 2023 revision (Unger et al.,
      PMID:36779427), group 21 "Primordial dwarfism and slender bone
      dysplasias", NOS 21-0230 "Saul-Wilson syndrome, COG4-related" (AD, OMIM
      618150). One row, one entry. The allelic biallelic COG4 congenital
      disorder of glycosylation is a separate entity and is not in this group
      -the gene alone does not place a disorder here.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: NOT_YET_DOCUMENTED
  notes: >-
    Ultra-rare. Fourteen affected individuals were described in the
    gene-discovery report; GeneReviews counted sixteen reported individuals.
    No population rate has been published.
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, 16 affected individuals have been reported."
    explanation: >-
      GeneReviews gives the reported case count, which is what stands in for a
      prevalence estimate here.
inheritance:
- name: Autosomal dominant, typically de novo
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  de_novo_rate: >-
    Typically de novo; sib recurrence has been observed in one family and is
    attributed to parental germline mosaicism.
  description: >-
    Heterozygous de novo COG4 variants. Offspring of an affected individual have
    a 50% risk of inheriting the variant.
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SWS is an autosomal dominant disorder typically caused by a de novo pathogenic variant. Sib recurrence has been observed in one family and is thought to result from germline mosaicism in a parent."
    explanation: >-
      States both the dominant de novo pattern and the single germline-mosaicism
      recurrence that qualifies it.
genetic:
- name: COG4
  gene_term:
    preferred_term: COG4
    term:
      id: hgnc:18620
      label: COG4
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  notes: >-
    COG4 (16q22.1) encodes a lobe-A subunit of the conserved oligomeric Golgi
    complex. Saul-Wilson syndrome is caused by a single recurrent amino acid
    substitution, p.Gly516Arg; only two COG4 variants have been reported, both
    producing that same change. This allelic specificity is unusual enough to be
    diagnostically useful - a different COG4 variant is not Saul-Wilson
    syndrome.
  evidence:
  - reference: PMID:30290151
    reference_title: "A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All affected subjects harbored heterozygous de novo variants in COG4, giving rise to the same recurrent amino acid substitution (p.Gly516Arg)."
    explanation: >-
      Establishes the gene and the single recurrent substitution.
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date only two COG4 variants, both resulting in a p.Gly516Arg missense change, have been reported."
    explanation: >-
      Confirms the allelic restriction at the level of reported variants.
pathophysiology:
- name: Recurrent COG4 p.Gly516Arg Substitution
  biological_scale: MOLECULAR
  role: trigger
  description: >-
    A heterozygous de novo missense change in a lobe-A subunit of the conserved
    oligomeric Golgi complex. Critically, this is not haploinsufficiency:
    patient fibroblasts have undiminished COG4 mRNA and protein, so the variant
    protein is present and acting, not absent.
  genes:
  - preferred_term: COG4
    term:
      id: hgnc:18620
      label: COG4
  genetic_context:
    functional_impact_category: UNKNOWN
    allele_type: missense
    variant_origin: DE_NOVO
    zygosity: HETEROZYGOUS
    description: >-
      A single recurrent heterozygous missense substitution. Its impact is not
      loss of function - COG4 mRNA and protein levels are preserved - and no
      published work assigns it to a named functional class, so
      functional_impact_category is recorded as UNKNOWN rather than guessed at.
  downstream:
  - target: Imbalanced Bidirectional Golgi Vesicular Traffic
  evidence:
  - reference: PMID:30290151
    reference_title: "A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Affected individuals' fibroblasts, whose COG4 mRNA and protein were not decreased"
    explanation: >-
      Rules out reduced COG4 abundance as the mechanism, which is what forces a
      non-loss-of-function reading of the variant.
  - reference: PMID:30290151
    reference_title: "A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The conserved oligomeric Golgi (COG) complex is involved in intracellular vesicular transport, and is composed of eight subunits distributed in two lobes, lobe A (COG1-4) and lobe B (COG5-8)."
    explanation: >-
      Identifies the complex and the lobe in which COG4 sits.
- name: Imbalanced Bidirectional Golgi Vesicular Traffic
  biological_scale: CELLULAR
  description: >-
    Patient fibroblasts show delayed anterograde vesicular trafficking from the
    ER to the Golgi together with accelerated retrograde recycling from the
    Golgi back to the ER. The disorder is therefore one of steady-state
    imbalance in both directions, not a simple block - a distinction that
    matters because it predicts a shrinking rather than a distended Golgi.
  cell_types:
  - preferred_term: dermal fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: endoplasmic reticulum to Golgi vesicle-mediated transport
    term:
      id: GO:0006888
      label: endoplasmic reticulum to Golgi vesicle-mediated transport
    modifier: DECREASED
  - preferred_term: retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum
    term:
      id: GO:0006890
      label: retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum
    modifier: INCREASED
  downstream:
  - target: Golgi Volume Loss and Stack Collapse
  - target: Intermittent neutropenia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Granulocyte development and release are secretion-dependent; grouped
      here as the most plausible route, which has not been investigated in
      this disorder.
  - target: Elevated liver transaminases
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Hepatocytes are among the most secretory cell types; grouped here, with
      no established mechanism.
  evidence:
  - reference: PMID:30290151
    reference_title: "A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "exhibited delayed anterograde vesicular trafficking from the ER to the Golgi and accelerated retrograde vesicular recycling from the Golgi to the ER"
    explanation: >-
      The measured bidirectional trafficking defect in patient cells.
- name: Golgi Volume Loss and Stack Collapse
  biological_scale: CELLULAR
  description: >-
    The altered steady-state equilibrium decreases Golgi volume and collapses
    the Golgi stacks - the structural consequence of removing more membrane
    retrogradely than arrives anterogradely.
  cellular_components:
  - preferred_term: Golgi apparatus
    term:
      id: GO:0005794
      label: Golgi apparatus
  biological_processes:
  - preferred_term: Golgi organization
    term:
      id: GO:0007030
      label: Golgi organization
    modifier: ABNORMAL
  downstream:
  - target: Selective Decorin Glycosylation Defect
  - target: Glypican Accumulation and Elevated wnt4 Signalling
  evidence:
  - reference: PMID:30290151
    reference_title: "A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "This altered steady-state equilibrium led to a decrease in Golgi volume, as well as morphologic abnormalities with collapse of the Golgi stacks."
    explanation: >-
      Documents both the volume loss and the morphological collapse.
- name: Selective Decorin Glycosylation Defect
  biological_scale: MOLECULAR
  description: >-
    Despite a visibly abnormal Golgi, protein glycosylation in patient serum and
    fibroblasts is not notably altered. The one demonstrated exception is
    decorin, a proteoglycan secreted into the extracellular matrix, whose
    Golgi-dependent glycosylation is altered. This selectivity is the reason the
    disease presents as a skeletal dysplasia rather than as a congenital
    disorder of glycosylation, and it is also the weakest link in the causal
    chain: no study has yet shown that altered decorin glycosylation is
    sufficient to produce the skeletal phenotype.
  biological_processes:
  - preferred_term: proteoglycan biosynthetic process
    term:
      id: GO:0030166
      label: proteoglycan biosynthetic process
    modifier: ABNORMAL
  downstream:
  - target: Profound Short Stature and Skeletal Dysplasia
  - target: Lamellar cataracts
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Decorin and related small leucine-rich proteoglycans are
      extracellular-matrix components of ocular tissue; grouped here as the most plausible
      route, which has not been shown directly.
  - target: Rod-cone retinal dystrophy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Grouped with the other ocular findings as a probable
      extracellular-matrix consequence; not demonstrated.
  - target: Hearing loss
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Conductive, sensorineural and mixed loss are reported; the conductive
      component is plausibly skeletal, but no mechanism has been established.
  - target: Cystic macular changes
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Grouped with the other ocular findings as a probable
      extracellular-matrix consequence; not demonstrated.
  evidence:
  - reference: PMID:30290151
    reference_title: "A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "protein glycosylation in sera and fibroblasts from affected subjects was not notably altered, but decorin, a proteoglycan secreted into the extracellular matrix, showed altered Golgi-dependent glycosylation"
    explanation: >-
      Establishes both the sparing of bulk glycosylation and the single
      demonstrated proteoglycan defect.
- name: Glypican Accumulation and Elevated wnt4 Signalling
  biological_scale: MOLECULAR
  description: >-
    The proteoglycan defect is not confined to decorin. Patient fibroblasts
    accumulate glypicans - heparan sulfate proteoglycans that gate several
    growth and bone-development pathways - and the same accumulation occurs in
    zebrafish embryos expressing COG4 p.G516R. Downstream, wnt4 transcripts rise
    selectively, and overexpressing wnt4 alone phenocopies the developmental
    defects, so the elevated wnt4 is doing causal work rather than marking the
    lesion. The Wnt inhibitor LGK974 partially corrects body length, which is
    the strongest evidence in this disorder that a downstream node is
    pharmacologically addressable.
  biological_processes:
  - preferred_term: heparan sulfate proteoglycan metabolic process
    term:
      id: GO:0030201
      label: heparan sulfate proteoglycan metabolic process
    modifier: ABNORMAL
  - preferred_term: non-canonical Wnt signaling pathway
    term:
      id: GO:0035567
      label: non-canonical Wnt signaling pathway
    modifier: INCREASED
  downstream:
  - target: Impaired Chondrocyte Differentiation and Secretome
  - target: Profound Short Stature and Skeletal Dysplasia
    description: >-
      Convergent-extension defects and shortened body length in the zebrafish
      model are the developmental route from glypican/wnt4 dysregulation to the
      growth phenotype.
  evidence:
  - reference: PMID:34595172
    reference_title: "A Dominant Heterozygous Mutation in COG4 Causes Saul-Wilson Syndrome, a Primordial Dwarfism, and Disrupts Zebrafish Development via Wnt Signaling."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "SWS fibroblasts accumulate glypicans, a group of heparan sulfate proteoglycans (HSPGs) critical for growth and bone development through multiple signaling pathways."
    explanation: >-
      Extends the proteoglycan defect from decorin to the glypicans in patient
      cells.
  - reference: PMID:34595172
    reference_title: "A Dominant Heterozygous Mutation in COG4 Causes Saul-Wilson Syndrome, a Primordial Dwarfism, and Disrupts Zebrafish Development via Wnt Signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we assessed wnt levels and found a selective increase of wnt4 transcripts in the presence of COG4 p.G516R"
    explanation: >-
      Identifies the specific signalling change downstream of glypican
      accumulation.
  - reference: PMID:34595172
    reference_title: "A Dominant Heterozygous Mutation in COG4 Causes Saul-Wilson Syndrome, a Primordial Dwarfism, and Disrupts Zebrafish Development via Wnt Signaling."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "overexpression of wnt4 mRNA phenocopies these developmental defects"
    explanation: >-
      Phenocopy by wnt4 alone is what makes the elevated wnt4 causal rather than
      correlative.
- name: Impaired Chondrocyte Differentiation and Secretome
  biological_scale: CELLULAR
  description: >-
    In a chondrocyte-relevant cell type carrying a CRISPR knock-in of the
    variant, 3D spheroids are smaller and apoptosis is increased - impaired in
    vitro chondrogenesis. The defect is largely non-cell-autonomous: adding
    wild-type cells or merely their conditioned medium rescues both cell death
    and spheroid size, pointing at missing secreted matrix components rather
    than an intrinsic block. Secretome analysis identifies MMP13 and IGFBP7,
    both chondro-osteogenic, as selectively under-secreted, and the cells show
    reduced MMP13 and COL10A1 differentiation markers with a delayed BMP2
    response. Notably, bulk N-glycans change only modestly, which reinforces
    that this is a trafficking and secretion disease rather than a
    glycosylation disease.
  cell_types:
  - preferred_term: chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  biological_processes:
  - preferred_term: chondrocyte differentiation
    term:
      id: GO:0002062
      label: chondrocyte differentiation
    modifier: DECREASED
  - preferred_term: protein secretion
    term:
      id: GO:0009306
      label: protein secretion
    modifier: DECREASED
  - preferred_term: apoptotic process
    term:
      id: GO:0006915
      label: apoptotic process
    modifier: INCREASED
  downstream:
  - target: Profound Short Stature and Skeletal Dysplasia
  - target: Skeletal fragility
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Under-secretion of chondro-osteogenic matrix components is the plausible
      route to fragile bone; not demonstrated directly.
  - target: Premature degenerative joint disease
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      The adult-onset consequence of the same abnormal cartilage matrix:
      chondrocytes that differentiate and secrete abnormally produce cartilage
      that wears out decades early.
  evidence:
  - reference: PMID:36393834
    reference_title: "COG4 mutation in Saul-Wilson syndrome selectively affects secretion of proteins involved in chondrogenesis in chondrocyte-like cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we found that cells carrying the COG4p.G516R variant made smaller spheroids and had increased apoptosis, indicating impaired in vitro chondrogenesis"
    explanation: >-
      The chondrogenic defect measured in a disease-relevant cell type.
  - reference: PMID:36393834
    reference_title: "COG4 mutation in Saul-Wilson syndrome selectively affects secretion of proteins involved in chondrogenesis in chondrocyte-like cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Adding WT cells or their conditioned medium reduced cell death and increased spheroid sizes of COG4p.G516R mutant cells, suggesting a deficiency in secreted matrix components."
    explanation: >-
      Rescue by conditioned medium alone establishes the defect as
      non-cell-autonomous - a secreted-factor deficiency.
  - reference: PMID:36393834
    reference_title: "COG4 mutation in Saul-Wilson syndrome selectively affects secretion of proteins involved in chondrogenesis in chondrocyte-like cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Mass spectrometry-based secretome analysis showed selectively impaired protein secretion, including MMP13 and IGFBP7 which are involved in chondrogenesis and osteogenesis."
    explanation: >-
      Names the specific under-secreted factors linking the Golgi lesion to the
      cartilage phenotype.
  - reference: PMID:36393834
    reference_title: "COG4 mutation in Saul-Wilson syndrome selectively affects secretion of proteins involved in chondrogenesis in chondrocyte-like cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Both SW1353 and HEK293T cells carrying COG4p.G516R showed very modest, cell-type dependent changes in N-glycans."
    explanation: >-
      Bulk glycosylation is near-normal, which is why this is a trafficking
      rather than a glycosylation disorder.
- name: Profound Short Stature and Skeletal Dysplasia
  biological_scale: ORGANISM
  role: consequence
  description: >-
    The clinical endpoint: profound short stature with distinctive craniofacial
    features, short distal phalanges of fingers and toes and often clubfoot,
    with cognition normal.
  downstream:
  - target: Profound short stature
    description: >-
      The growth endpoint of the extracellular-matrix defect.
  - target: Short distal phalanges of fingers
    description: >-
      Acral skeletal expression of the same dysplasia.
  - target: Clubfoot
    description: >-
      Skeletal/positional consequence of the dysplasia.
  - target: Distinctive craniofacial features
    description: >-
      Craniofacial skeletal expression of the dysplasia.
  - target: Atlantoaxial instability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Cervical skeletal consequence, and the finding that drives the activity
      restriction; the specific route from altered proteoglycan glycosylation
      to ligamentous or odontoid instability is not established.
  - target: Delayed speech and language development
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Early speech and motor development are delayed while cognition is
      normal; grouped with the developmental consequences, with no established
      mechanism.
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Saul-Wilson syndrome (SWS) is a skeletal dysplasia characterized by profound short stature, distinctive craniofacial features, short distal phalanges of fingers and toes, and often clubfoot."
    explanation: >-
      GeneReviews defines the clinical endpoint.
phenotypes:
- category: Growth
  name: Profound short stature
  phenotype_term:
    preferred_term: Severe short stature
    term:
      id: HP:0003510
      label: Severe short stature
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a skeletal dysplasia characterized by profound short stature, distinctive craniofacial features"
    explanation: >-
      GeneReviews names profound short stature as the defining feature.
- category: Skeletal
  name: Short distal phalanges of fingers
  phenotype_term:
    preferred_term: Short distal phalanx of finger
    term:
      id: HP:0009882
      label: Short distal phalanx of finger
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "short distal phalanges of fingers and toes, and often clubfoot"
    explanation: >-
      GeneReviews lists short distal phalanges among the defining features.
- category: Skeletal
  name: Clubfoot
  phenotype_term:
    preferred_term: Clubfoot
    term:
      id: HP:0001762
      label: Talipes equinovarus
  frequency: FREQUENT
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "short distal phalanges of fingers and toes, and often clubfoot"
    explanation: >-
      GeneReviews records clubfoot as often present.
- category: Craniofacial
  name: Distinctive craniofacial features
  phenotype_term:
    preferred_term: Distinctive craniofacial appearance
    term:
      id: HP:0001999
      label: Abnormal facial shape
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "profound short stature, distinctive craniofacial features"
    explanation: >-
      GeneReviews names the facial gestalt among the defining features.
- category: Neurodevelopmental
  name: Delayed speech and language development
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  frequency: FREQUENT
  description: >-
    Early development, primarily speech and motor, is delayed - but cognition is
    normal, so the delay should not be read as intellectual disability. This is
    the contrast with Sanjad-Sakati syndrome in the same nosology group.
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early development (primarily speech and motor) is delayed; cognition is normal."
    explanation: >-
      GeneReviews records the delay and, in the same sentence, that cognition is
      spared.
- category: Ocular
  name: Lamellar cataracts
  phenotype_term:
    preferred_term: Lamellar cataract
    term:
      id: HP:0000518
      label: Cataract
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other findings can include hearing loss (conductive, sensorineural, and mixed), lamellar cataracts, and/or rod-cone retinal dystrophy."
    explanation: >-
      GeneReviews lists lamellar cataract among the variable findings.
- category: Ocular
  name: Rod-cone retinal dystrophy
  phenotype_term:
    preferred_term: Rod-cone dystrophy
    term:
      id: HP:0000510
      label: Rod-cone dystrophy
  frequency: VERY_FREQUENT
  description: >-
    GeneReviews lists this among the variable findings, but the cohort study
    that examined it directly found a pigmentary retinopathy in all four
    patients who had a detailed ophthalmic exam at the NIH Clinical Center, and
    also in several patients whose records were reviewed. The frequency here
    follows the systematic examination rather than the summary listing - the
    two disagree because a retinopathy that is asymptomatic in a young child is
    only found if it is looked for.
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "lamellar cataracts, and/or rod-cone retinal dystrophy"
    explanation: >-
      GeneReviews lists rod-cone retinal dystrophy among the variable findings.
      PARTIAL because the "and/or" phrasing understates the frequency found on
      systematic examination.
  - reference: PMID:31949312
    reference_title: "Defining the clinical phenotype of Saul-Wilson syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Retinal degeneration consistent with a rod-cone dystrophy (retinitis pigmentosa) was present in all four patients who underwent detailed ophthalmic exams at the NIH Clinical Center; it was also reported in several patients whose records were reviewed."
    explanation: >-
      The systematic ophthalmic examination behind the VERY_FREQUENT
      classification - four of four examined.
- category: Auditory
  name: Hearing loss
  phenotype_term:
    preferred_term: Hearing loss (conductive, sensorineural or mixed)
    term:
      id: HP:0000365
      label: Hearing impairment
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other findings can include hearing loss (conductive, sensorineural, and mixed)"
    explanation: >-
      GeneReviews records hearing loss of all three types among the variable
      findings.
- category: Skeletal
  name: Atlantoaxial instability
  phenotype_term:
    preferred_term: Atlantoaxial instability
    term:
      id: HP:0003467
      label: Atlantoaxial instability
  frequency: OCCASIONAL
  description: >-
    Potentially the most consequential finding to look for, since it drives the
    activity restriction below and the concern about C1-C2 subluxation and cord
    compression.
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "possible C1-C2 subluxation and/or spinal cord compression"
    explanation: >-
      GeneReviews names C1-C2 subluxation and cord compression among the
      manifestations to address.
- category: Hematologic
  name: Intermittent neutropenia
  phenotype_term:
    preferred_term: Intermittent neutropenia
    term:
      id: HP:0001875
      label: Decreased total neutrophil count
  frequency: VERY_FREQUENT
  description: >-
    A laboratory finding rather than a structural one, and easy to miss in a
    disorder framed as a skeletal dysplasia. Two things make the timing matter:
    it is intermittent without cyclic periodicity, so a single normal count
    does not exclude it, and it was absent in all four individuals whose counts
    were taken in the first two months of life - a normal neonatal count says
    nothing. In everyone tested beyond that window it was present.
  evidence:
  - reference: PMID:31949312
    reference_title: "Defining the clinical phenotype of Saul-Wilson syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although neutropenia was not appreciated in any person when blood counts were obtained within the first two months of life (n=4), it was noted in all individuals for whom values were available for analysis (n=12)."
    explanation: >-
      Gives the actual denominator - present in 12 of 12 tested beyond the
      neonatal window - which is what makes this VERY_FREQUENT rather than the
      abstract's unquantified "frequently observed".
  - reference: PMID:31949312
    reference_title: "Defining the clinical phenotype of Saul-Wilson syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This neutropenia was intermittent, but did not have any noticeable cyclic periodicity."
    explanation: >-
      The intermittency without periodicity, which is why a single count cannot
      exclude the finding.
- category: Skeletal
  name: Premature degenerative joint disease
  phenotype_term:
    preferred_term: Premature osteoarthritis
    term:
      id: HP:0003088
      label: Premature osteoarthritis
    onset:
      onset_category: YOUNG_ADULT
  frequency: OCCASIONAL
  description: >-
    Adult-onset, and therefore under-ascertained in a cohort weighted toward
    children. Two adults in their twenties had degenerative joint disease, one
    requiring joint replacement on three occasions - a consequence of the
    abnormal cartilage extracellular matrix that becomes clinically dominant
    long after the growth phenotype has stabilized.
  evidence:
  - reference: PMID:31949312
    reference_title: "Defining the clinical phenotype of Saul-Wilson syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Premature degenerative joint disease was seen in two adults in their 20s, with early joint replacement in one (see supplementary figure S2J)."
    explanation: >-
      The cohort observation, including the age at onset that makes this an
      adult complication rather than a childhood feature.
- category: Hepatic
  name: Elevated liver transaminases
  phenotype_term:
    preferred_term: Elevated circulating hepatic transaminase concentration
    term:
      id: HP:0002910
      label: Elevated circulating hepatic transaminase concentration
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:31949312
    reference_title: "Defining the clinical phenotype of Saul-Wilson syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Novel findings included elevation of liver transaminases, skeletal fragility, rod-cone dystrophy, and cystic macular changes."
    explanation: >-
      One of the findings newly recognized when the cohort phenotype was
      defined.
- category: Skeletal
  name: Skeletal fragility
  phenotype_term:
    preferred_term: Increased susceptibility to fractures
    term:
      id: HP:0002659
      label: Increased susceptibility to fractures
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:31949312
    reference_title: "Defining the clinical phenotype of Saul-Wilson syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Novel findings included elevation of liver transaminases, skeletal fragility, rod-cone dystrophy, and cystic macular changes."
    explanation: >-
      Skeletal fragility named among the novel cohort findings.
- category: Ocular
  name: Cystic macular changes
  phenotype_term:
    preferred_term: Cystoid macular changes
    term:
      id: HP:0011505
      label: Cystoid macular edema
  frequency: FREQUENT
  description: >-
    Documented in two of the four patients who had a detailed ophthalmic exam,
    so common enough to warrant looking for, but on a small denominator.
  evidence:
  - reference: PMID:31949312
    reference_title: "Defining the clinical phenotype of Saul-Wilson syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A pigmentary retinopathy consistent with a rod-cone dystrophy was noted in all four patients, whereas macular cystic changes were documented in two of the four individuals seen at the NIH Clinical Center."
    explanation: >-
      Gives the numerator and denominator for both retinal findings; two of
      four supports FREQUENT.
diagnosis:
- name: Molecular genetic testing of COG4
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C15709
      label: Genetic Testing
  presence: Heterozygous COG4 c.1546G>A p.(Gly516Arg)
  description: >-
    Unusually straightforward for a rare disease: every reported patient
    carries the same de novo heterozygous substitution, so a targeted single
    variant test confirms the diagnosis. Note that other COG4 variants cause a
    biallelic congenital disorder of glycosylation with a different phenotype,
    so the gene name alone is not the answer - the specific allele is.
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of SWS is established in a proband with marked short stature, typical facial and skeletal features, and a heterozygous pathogenic variant in COG4 identified by molecular genetic testing."
    explanation: >-
      The GeneReviews diagnostic criterion.
animal_models:
- name: Zebrafish COG4 p.Gly516Arg expressing embryos
  species: Zebrafish
  genotype: Expression of human COG4 p.Gly516Arg mRNA in wild-type embryos
  publication: PMID:34595172
  description: >-
    An overexpression rather than a knock-in model, and that is the caveat to
    carry through everything below - but it reproduces the two things the human
    disorder needs explaining: short body length and defective cartilage
    chondrocyte intercalation, both traceable to glypican accumulation and a
    selective rise in wnt4.
  modeled_mechanisms:
  - target: Glypican Accumulation and Elevated wnt4 Signalling
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      The mechanism was established in this model, not merely reproduced by it -
      glypican accumulation, the selective wnt4 increase, the phenocopy on wnt4
      overexpression, and the partial pharmacological rescue are all zebrafish
      results.
    limitations: >-
      Dominant human mRNA expressed in a wild-type background, so the dose is
      not physiological and a dominant-negative artefact cannot be formally
      excluded. The LGK974 rescue is also biphasic - correcting at low
      concentration and worsening at slightly higher - which is what one expects
      of a pathway that must be tuned rather than switched off, but it makes the
      rescue a weaker causal argument than a clean dose-response would be.
    readouts:
    - name: Larval body length under Wnt inhibition
      target: Glypican Accumulation and Elevated wnt4 Signalling
      direction: RESTORED
      interpretation: >-
        Partial pharmacological rescue supports Wnt signalling as the effector
        arm, with the biphasic response as the stated caveat.
      evidence:
      - reference: PMID:34595172
        reference_title: "A Dominant Heterozygous Mutation in COG4 Causes Saul-Wilson Syndrome, a Primordial Dwarfism, and Disrupts Zebrafish Development via Wnt Signaling."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "LGK974, an inhibitor of Wnt signaling, corrects the shortened body length at low concentrations but amplifies it at slightly higher concentrations."
        explanation: >-
          The rescue and its biphasic limitation, quoted together because they
          are one result.
    evidence:
    - reference: PMID:34595172
      reference_title: "A Dominant Heterozygous Mutation in COG4 Causes Saul-Wilson Syndrome, a Primordial Dwarfism, and Disrupts Zebrafish Development via Wnt Signaling."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These animals show phenotypes consistent with convergent extension (CE) defects during gastrulation, shortened body length, and malformed jaw cartilage chondrocyte intercalation at larval stages."
      explanation: >-
        The developmental phenotype that makes this model informative for the
        glypican/wnt4 node.
- name: C. elegans cogc-4(av107)
  species: Caenorhabditis elegans
  genotype: cogc-4(av107) - CRISPR-Cas9 knock-in of the orthologous glycine-to-arginine substitution
  publication: PMID:33688625
  description: >-
    A genuine negative result, and the more rigorous model design of the two:
    an endogenous knock-in of the orthologous substitution rather than
    overexpression of the human protein. It produced no detectable phenotype -
    not on observation, not under heat or Paraquat stress, and not on RNAi
    against the other seven COG subunits. Recorded because a published negative
    that took this much work to establish should not have to be rediscovered.
  modeled_mechanisms:
  - target: Recurrent COG4 p.Gly516Arg Substitution
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >-
      The same substitution, made endogenously in the orthologous gene, causes
      nothing detectable in the worm. This is a constraint on how the human
      variant is understood: whatever it does, it is not a cell-autonomous
      insult that any COG4-expressing organism would register.
    limitations: >-
      Absence of a phenotype under the assays used is not absence of a
      molecular defect - the authors say so themselves, and recommend directly
      assessing Golgi function rather than screening for organismal phenotypes.
      C. elegans also lacks cartilage and endochondral bone entirely, so the
      tissue in which the human disease manifests has no counterpart to
      examine.
    evidence:
    - reference: PMID:33688625
      reference_title: "Saul-Wilson Syndrome Missense Allele Does Not Show Obvious Golgi Defects in a C. elegans Model."
      supports: REFUTE
      evidence_source: MODEL_ORGANISM
      snippet: "Our data suggest that this mutation in cogc-4(av107) worms does not lead to a detectable phenotype."
      explanation: >-
        The negative conclusion, stated by the authors.
    - reference: PMID:33688625
      reference_title: "Saul-Wilson Syndrome Missense Allele Does Not Show Obvious Golgi Defects in a C. elegans Model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We used a variety of assays including stressing the worms using heat and Paraquat, as well as RNAi against the 7 other COG complex subunit genes in an attempt to uncover a phenotype."
      explanation: >-
        Documents the breadth of the search, which is what distinguishes this
        from a model that was simply not looked at hard enough.
treatments:
- name: Skeletal Dysplasia and Physiatry Management
  description: >-
    Care through a skeletal dysplasia or physiatry clinic - orthopedist,
    occupational and physical therapy, rehabilitation - covering clubfoot
    repair, possible C1-C2 subluxation or cord compression, mobility after
    clubfoot repair, and osteoarticular pain.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: orthopedic surgical procedure
    term:
      id: NCIT:C16186
      label: Orthopedic Surgical Procedure
  target_phenotypes:
  - preferred_term: Clubfoot
    term:
      id: HP:0001762
      label: Talipes equinovarus
  - preferred_term: Atlantoaxial instability
    term:
      id: HP:0003467
      label: Atlantoaxial instability
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Skeletal dysplasia or physiatry clinic (orthopedist, OT & PT, rehabilitation specialist) to address repair of clubfoot"
    explanation: >-
      GeneReviews management recommendation.
- name: Avoidance of Gymnastics and Trampolining
  description: >-
    An explicit "agents and circumstances to avoid" item: gymnastics and
    trampoline jumping are contraindicated until atlanto-axial instability has
    been excluded. This is a safety instruction, not a general activity
    recommendation, and it is time-limited by the imaging result.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Atlantoaxial instability
    term:
      id: HP:0003467
      label: Atlantoaxial instability
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Participation in gymnastics and jumping on a trampoline until atlanto-axial instability is excluded."
    explanation: >-
      The GeneReviews Agents/Circumstances to Avoid entry, quoted directly.
- name: Sensory Surveillance and Treatment
  description: >-
    Standard treatment for cataracts, retinal dystrophy and hearing loss, with
    routine surveillance for each, alongside monitoring of growth, feeding,
    development and musculoskeletal status.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Cataract
    term:
      id: HP:0000518
      label: Cataract
  - preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "standard treatment for feeding issues, speech delay, cataracts and retinal dystrophy, and hearing loss"
    explanation: >-
      GeneReviews management recommendation.
- name: Growth Hormone Supplementation (Ineffective)
  description: >-
    Curated as a negative result rather than a recommendation. A retrospective
    analysis comparing height-for-age model fits before and after starting
    growth hormone found no apparent effect on height in Saul-Wilson syndrome.
    That is the expected outcome for a cell-intrinsic secretion and matrix
    defect, and it matters practically: the same paper warns against
    unnecessarily aggressive nutritional intervention aimed at a weight target
    that is not achievable in a genetically determined primordial dwarfism.
  therapeutic_modality: PROTEIN_REPLACEMENT
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: somatropin
      term:
        id: NCIT:C837
        label: Somatropin
  evidence:
  - reference: PMID:32652690
    reference_title: "Growth in individuals with Saul-Wilson syndrome."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "we performed statistical comparisons of height-for-age model fits before and after initiation of growth hormone supplementation, and found that this therapy does not appear to influence height in individuals with SWS"
    explanation: >-
      Refutes growth hormone as an effective height intervention in this
      disorder, which is why the entry records it as a negative result.
- name: Genetic Counseling
  description: >-
    Counseling covers the de novo dominant mechanism, the 50% transmission risk
    from an affected individual, and the germline-mosaicism recurrence risk that
    the single reported sib pair implies.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:32078278
    reference_title: "Saul-Wilson Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The risk to offspring of an individual with SWS of inheriting the COG4 pathogenic variant is 50%."
    explanation: >-
      GeneReviews genetic counseling guidance.
discussions:
- discussion_id: sws_decorin_sufficiency
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Selective Decorin Glycosylation Defect
  prompt: >-
    Is altered decorin glycosylation sufficient to produce the Saul-Wilson
    skeletal phenotype, or is it a marker of a broader extracellular-matrix
    defect that has not yet been measured?
  rationale: >-
    Decorin is the only protein shown to be abnormally glycosylated in patient
    cells, and bulk glycosylation is preserved - so it carries the entire
    explanatory weight between a shrunken Golgi and a skeletal dysplasia. That
    is a lot to rest on one assay of one proteoglycan, and no reported
    experiment tests whether correcting or phenocopying the decorin defect
    changes the skeletal outcome.
references:
- reference: PMID:32078278
  title: "Saul-Wilson Syndrome."
  tags:
  - GeneReviews
- reference: PMID:30290151
  title: "A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation."
- reference: PMID:31949312
  title: "Defining the clinical phenotype of Saul-Wilson syndrome."
- reference: PMID:34595172
  title: "A Dominant Heterozygous Mutation in COG4 Causes Saul-Wilson Syndrome, a Primordial Dwarfism, and Disrupts Zebrafish Development via Wnt Signaling."
- reference: PMID:36393834
  title: "COG4 mutation in Saul-Wilson syndrome selectively affects secretion of proteins involved in chondrogenesis in chondrocyte-like cells."
- reference: PMID:32652690
  title: "Growth in individuals with Saul-Wilson syndrome."
- reference: PMID:33688625
  title: "Saul-Wilson Syndrome Missense Allele Does Not Show Obvious Golgi Defects in a C. elegans Model."
📚

References & Deep Research

References

7
PMID:32078278
Saul-Wilson Syndrome.
No top-level findings curated for this source.
PMID:30290151
A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation.
No top-level findings curated for this source.
PMID:31949312
Defining the clinical phenotype of Saul-Wilson syndrome.
No top-level findings curated for this source.
PMID:34595172
A Dominant Heterozygous Mutation in COG4 Causes Saul-Wilson Syndrome, a Primordial Dwarfism, and Disrupts Zebrafish Development via Wnt Signaling.
No top-level findings curated for this source.
PMID:36393834
COG4 mutation in Saul-Wilson syndrome selectively affects secretion of proteins involved in chondrogenesis in chondrocyte-like cells.
No top-level findings curated for this source.
PMID:32652690
Growth in individuals with Saul-Wilson syndrome.
No top-level findings curated for this source.
PMID:33688625
Saul-Wilson Syndrome Missense Allele Does Not Show Obvious Golgi Defects in a C. elegans Model.
No top-level findings curated for this source.

Deep Research

1
Claude Code ▸
I'll research Saul-Wilson Syndrome using web search to compile accurate, citable information for this report.
claude-haiku-4-5-20251001, claude-sonnet-5 11 citations 2026-08-27T04:09:14.159599

I'll research Saul-Wilson Syndrome using web search to compile accurate, citable information for this report.

I have sufficient material now. Let me do a couple final targeted searches on treatment/experimental therapeutics (LGK974/Wnt inhibitor translational angle) and the original 1990 Saul-Wilson description plus ICD-10/Orphanet code, then compile the report.

I now have comprehensive, well-sourced material. Compiling the full report.

Comprehensive Research Report: Saul-Wilson Syndrome

1. Disease Information

Overview. Saul-Wilson syndrome (SWS; also historically termed "microcephalic osteodysplastic dysplasia, Saul-Wilson type") is an ultra-rare, sporadic (typically de novo) skeletal dysplasia — a form of primordial dwarfism — characterized by profound prenatal-onset short stature, a distinctive progeroid craniofacial appearance, short distal phalanges, frequent clubfoot, and a recognizable ocular/auditory/hematologic complication profile, with normal cognition despite early motor and speech delay. It was molecularly solved in 2018 as a Golgi-trafficking disorder caused by a single recurrent gain-of-function missense variant in COG4 (Ferreira et al., 2018, PMID: 30290151).

Key identifiers: - OMIM: #618150 (SWILS) — omim.org/entry/618150 - Gene locus (OMIM): COG4, 606976 (16q22.1) - Orphanet: ORPHA85172 — Microcephalic osteodysplastic dysplasia, Saul-Wilson type - MONDO: MONDO:0019407 - ICD-10-CM: Q78.8 (Other specified osteochondrodysplasias) - MeSH/MedGen: Microcephalic osteodysplastic dysplasia, Saul-Wilson type (Concept ID C1300285) - GeneReviews:* NBK554080 (Ferreira, Lee, Huang — updated periodically)

Synonyms: Saul-Wilson syndrome; SWILS; microcephalic osteodysplastic dysplasia, Saul-Wilson type; MOPD, Saul-Wilson type (not to be confused with unrelated MOPD I/II/III entities).

Evidence basis. All current disease-level knowledge derives from aggregated case-series/cohort resources (a single worldwide cohort tracked chiefly through the NICHD/Ferreira group and the Undiagnosed Diseases Network), not large EHR populations — reflecting the disorder's extreme rarity (fewer than ~20 molecularly confirmed individuals reported worldwide as of the most recent literature).

History. First clinically delineated by Saul & Wilson in two unrelated boys (Am J Med Genet. 1990;35(3):388-393), building on an original 1982 case report. The molecular cause remained unknown for 28 years until whole-exome sequencing across an international cohort identified the causal COG4 variant in 2018 (commentary: PMID 30548960, "The Saul-Wilson syndrome from its early days until now").

2. Etiology

Disease causal factor — purely genetic, monogenic, dominant gain-of-function. Saul-Wilson syndrome is caused by a single recurrent heterozygous, virtually always de novo missense substitution in COG4 (Conserved Oligomeric Golgi complex subunit 4): c.1546G>A or c.1546G>C, both producing the identical protein change p.Gly516Arg (G516R). Ferreira et al. (2018) identified this variant in all 14 unrelated probands sequenced across seven institutions using varied sequencing platforms and pipelines — an extraordinary degree of recurrence-at-a-single-residue for a Mendelian disorder (PMID 30290151).

"All affected subjects harbored heterozygous de novo variants in COG4, giving rise to the same recurrent amino acid substitution (p.Gly516Arg)." — Ferreira et al. 2018

Genetic risk factors. No susceptibility loci or modifier genes have been described; the disorder is fully explained by this single recurrent variant. No second causal gene has been reported to date (as of the literature reviewed, 2018–2026).

Environmental / lifestyle risk factors. None identified or plausible — this is a purely genetic, single-gene disorder with no known environmental trigger, infectious agent, or lifestyle contributor.

Protective factors. None described in the literature.

Gene-environment interactions. Not applicable/not reported; no environmental modifiers of expressivity have been documented.

Mechanism of recurrence (parental origin). No affected individual has had an affected parent; all reported cases are simplex with de novo variants confirmed by parental testing. Recurrence risk to siblings of an affected proband is nonetheless slightly elevated above general-population risk due to the possibility of parental germline mosaicism, which has been confirmed in at least one family (GeneReviews, NBK554080). Offspring of an affected individual would face a 50% transmission risk (autosomal dominant).

3. Phenotypes

Phenotype frequencies below are drawn from the two principal cohort papers — Ferreira et al. 2018 (n=14, molecular discovery cohort) and the dedicated phenotyping study "Defining the clinical phenotype of Saul-Wilson syndrome" (Genetics in Medicine, 2020; nature.com/articles/s41436-019-0737-1), which performed retrospective chart review and radiograph assessment of all 14–16 known individuals.

Growth (prenatal and postnatal — signs)

  • Profound short stature with prenatal onset, sharply diverging from population norms within the first months of life. HP:0001511 (Intrauterine growth retardation), HP:0008897 (Postnatal growth retardation), HP:0004322 (Short stature).
  • Birth length 44.1 ± 3.6 cm (Z ≈ −2.3); birth weight 2.09 ± 0.2 kg (Z ≈ −2.4); birth OFC 31.7 ± 1.6 cm (Z ≈ −2.0) — despite a mean gestational age of ~37 weeks (PMID 32652690, "Growth in individuals with Saul-Wilson syndrome," Ferreira et al. 2020).
  • Final/adult height (3 skeletally mature individuals): mean 107.6 ± 1.9 cm (range 106–109.7 cm), Z-score −4 to −8.5 SD — equivalent to a typical 4–5-year-old's stature.
  • Relative macrocephaly: "Head circumference in all individuals with SWS exceeds the height by more than 2 SD, with consequent relative macrocephaly," despite progressive absolute microcephaly with age (PMID 32652690).
  • Growth hormone treatment does not improve height (p = 0.052–0.489 across comparisons) — an important negative treatment-response finding.

Craniofacial (signs)

  • Prominent/bulging forehead with visible scalp veins; large/delayed-closing anterior fontanel (HP:0000260); sparse scalp hair and eyebrows; prominent eyes; narrow nasal bridge with convex/beaked nose; broad columella; thin upper lip; mild micrognathia; progeroid facial appearance in infancy — a striking, diagnostically useful gestalt.

Skeletal (signs)

  • Clubfoot/talipes (10/14, ~71%)
  • Short distal phalanges of fingers and toes / brachytelephalangy (12/14, ~86%)
  • Coxa valga and long-bone overtubulation
  • Pectus deformity (5/14, ~36%)
  • Platyspondyly and other spinal abnormalities
  • Bone fragility with fractures from minimal trauma (4/14, ~29%)
  • Premature osteoarthritis in adulthood, in some cases requiring joint replacement surgery in the third decade of life
  • Cervical spinal cord compression / cranio-cervical stenosis (3/7 in the phenotype cohort) — a serious, potentially treatment-refractory complication (see below).

Ocular (signs, 10/13 developed findings, ~77%)

  • Lamellar cataracts, typically appearing in early childhood
  • Rod-cone retinal dystrophy (5/9, ~56%)
  • Cystic macular changes (novel finding reported in the 2020 phenotyping study)
  • Blue sclerae in infancy

Auditory (signs)

  • Hearing loss of conductive, sensorineural, or mixed type, which may progress over time

Developmental / neurological

  • Speech delay (8/11, ~73%); motor delay (12/14, ~86%)
  • Cognition is normal in all reported individuals — a distinguishing feature from many other primordial dwarfism/skeletal dysplasia syndromes.

Laboratory abnormalities

  • Intermittent neutropenia — present in all 12 individuals tested (12/12); occasionally warranting monitoring or G-CSF if recurrent infection occurs.
  • Elevated hepatic transaminases (6–8 individuals) — a novel finding highlighted in the 2020 phenotyping paper.

Radiological (novel/imaging)

  • Ventriculomegaly on brain MRI (5/9, ~56%)

Quality of life

No dedicated EQ-5D/SF-36 disease-specific quality-of-life instrument data have been published; QoL impact is inferred qualitatively from the multidisciplinary management literature (mobility limitation from skeletal fragility/clubfoot, visual impairment from cataracts/retinal dystrophy, hearing impairment, and complications of cervical stenosis).

Study conclusion: "Saul-Wilson syndrome presents a remarkably uniform phenotype" across the reported cohort — an unusually tight genotype-phenotype correlation for a monogenic disorder, consistent with the single recurrent causal variant.

Suggested HPO terms: HP:0001511 (IUGR), HP:0008897 (postnatal growth retardation), HP:0003510 (short limb), HP:0004322 (short stature), HP:0011220 (prominent forehead), HP:0000260 (wide anterior fontanel), HP:0000527 (sparse eyebrow), HP:0000268 (dolichocephaly-type descriptors as applicable), HP:0000486 (strabismus if present), HP:0010442 (polydactyly — not typical, omit), HP:0001818 (clubfoot/talipes), HP:0009843 (brachytelephalangy), HP:0000518 (cataract), HP:0000510 (rod-cone dystrophy), HP:0000407 (sensorineural hearing loss), HP:0000405 (conductive hearing loss), HP:0001875 (neutropenia), HP:0002910 (elevated hepatic transaminase), HP:0002370 (motor delay), HP:0000750 (speech delay), HP:0002650 (scoliosis/spinal deformity as relevant), HP:0003042 (elbow dislocation — check applicability), HP:0002650, HP:0002098 (respiratory as relevant), HP:0002415 (spinal cord compression).

4. Genetic/Molecular Information

Causal gene: COG4 (Component of Oligomeric Golgi complex 4), OMIM *606976, HGNC:23054, chromosome 16q22.1.

Pathogenic variant: A single recurrent missense substitution, c.1546G>A or c.1546G>C, p.(Gly516Arg), ClinVar-classified pathogenic. No other COG4 variant, and no other gene, has been implicated in Saul-Wilson syndrome to date. Because this is a single-position recurrent variant (not a deletion/duplication or LOF spectrum), gene-targeted deletion/duplication analysis is not useful for diagnosis — targeted Sanger/NGS confirmation of the specific p.Gly516Arg change, or exome/genome sequencing, is the recommended testing strategy (GeneReviews NBK554080).

Variant classification/type: Missense, gain-of-function (not loss-of-function).

Allele frequency: Absent from population databases (gnomAD) — consistent with its universally de novo origin and severe phenotype.

Somatic vs. germline: Germline (constitutional), heterozygous, de novo in essentially all reported probands; parental germline mosaicism documented in at least one family.

Functional consequence — gain-of-function, not loss-of-function. This is a critical, well-established mechanistic distinction from COG4-congenital disorder of glycosylation (COG4-CDG), caused by biallelic loss-of-function COG4 variants:

Feature Saul-Wilson syndrome COG4-CDG
Variant type Heterozygous, recurrent p.G516R Biallelic LOF (nonsense/frameshift/splice)
COG4 protein/mRNA level Normal Reduced/absent
Vesicular trafficking Accelerated retrograde Golgi→ER; delayed anterograde ER→Golgi Generally impaired/reduced trafficking
N-glycosylation (serum) Normal Abnormal (hallmark CDG pattern)
Neurological involvement None (normal cognition) Seizures, hypotonia, intellectual disability
Severity Severe skeletal dysplasia, non-lethal Often lethal in infancy

Mechanistically, in SWS patient fibroblasts, COG4 mRNA and protein levels are not decreased, and Golgi volume is markedly reduced (~2.8-fold after normalization to nuclear volume), with only 51–55% of cells showing normal Golgi morphology (vs. 94% in controls) — cis/trans-Golgi stack collapse and abnormal co-localization are seen. Brefeldin A challenge assays show faster retrograde and slower anterograde Golgi reformation kinetics in patient cells (Ferreira et al. 2018, PMID 30290151):

Affected individuals' fibroblasts... "exhibited delayed anterograde vesicular trafficking from the ER to the Golgi and accelerated retrograde vesicular recycling from the Golgi to the ER. This altered steady-state equilibrium led to a decrease in Golgi volume, as well as morphologic abnormalities with collapse of the Golgi stacks."

Modifier genes: None identified.

Epigenetics: No DNA methylation, histone, or chromatin studies specific to SWS have been published.

Chromosomal abnormalities: None — this is a point-mutation disorder, not a copy-number or structural chromosomal condition.

Comparative/orthology note: COG4 belongs to the CATCHR (complexes associated with tethering containing helical rods) family and is one of eight subunits of the hetero-octameric COG vesicle-tethering complex governing intra-Golgi and retrograde Golgi-to-ER trafficking.

5. Environmental Information

No environmental factors, lifestyle exposures, toxins, or infectious agents are implicated in Saul-Wilson syndrome causation — this is a fully penetrant, single-variant Mendelian condition with no reported gene-environment modulation of expressivity or severity in the literature reviewed.

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

  1. Molecular trigger: COG4 c.1546G>C/A → p.Gly516Arg substitution in the COG4 subunit of the octameric COG vesicle-tethering complex (GO:0017119 COG complex).
  2. Cellular/organelle consequence — dysregulated vesicular trafficking: The mutant subunit remains stably incorporated into the COG complex (unlike COG4-CDG LOF alleles) but shifts the steady-state kinetic balance of Golgi trafficking: anterograde ER→Golgi transport is delayed while retrograde Golgi→ER transport is accelerated (GO:0006890 retrograde vesicle-mediated transport, Golgi to ER; GO:0006888 ER to Golgi vesicle-mediated transport). This is interpreted as a gain-of-function mechanism (PMID 30290151).
  3. Golgi structural consequence: Reduced Golgi volume (~2.8-fold), collapsed cis/trans-Golgi stacks, and abnormal Golgi compartment co-localization in patient fibroblasts.
  4. Glycoprotein/proteoglycan processing defect: Altered Golgi-dependent glycosylation of secreted proteoglycans. Decorin (a small leucine-rich proteoglycan) shows aberrant glycosaminoglycan (GAG) chain elongation both intracellularly and extracellularly. Notably, bulk serum N- and O-linked glycosylation is normal — the defect is selective, not a global CDG-type glycosylation failure.
  5. Selective secretome impairment in chondrocyte-like cells: Mass-spectrometry secretome profiling shows selectively impaired secretion of proteins essential to chondrogenesis/osteogenesis, notably MMP13 and IGFBP7 (Xia et al. 2022, PMID 36393834, Front Cell Dev Biol):

"The Saul-Wilson syndrome COG4p.G516R variant selectively affects the secretion of multiple proteins, especially in chondrocyte-like cells which could further cause pleiotropic defects including hampering long bone growth in SWS individuals."

Mutant chondrocyte-like cells show "reduced expression of chondrogenic differentiation markers, MMP13 and COL10A1 and delayed response to BMP2," form smaller spheroids with increased apoptosis in 3D chondrogenesis assays, and this defect is non-cell-autonomously rescuable: "Adding WT cells or their conditioned medium reduced cell death and increased spheroid sizes of COG4p.G516R mutant cells" — implicating a deficient secreted paracrine factor rather than a purely intracellular chondrocyte defect.

  1. Proteoglycan accumulation — glypican/Wnt axis: SWS patient cells accumulate glypicans (a heparan-sulfate proteoglycan family regulating growth-factor signaling, including Wnt). This links the Golgi trafficking defect to a specific downstream signaling pathway.
  2. Wnt-pathway dysregulation (zebrafish model, PMID 34595172, Ng et al., Dis Model Mech 2021):* Zebrafish expressing COG4^p.G516R^ show selective elevation of wnt4*** transcripts, and overexpression of wnt4 mRNA alone reproduces the developmental phenotype, establishing causality:

"These animals show phenotypes consistent with convergent extension (CE) defects during gastrulation, shortened body length, and malformed jaw cartilage chondrocyte intercalation at larval stages."

Body length reduction reaches ~18% at 3 days post-fertilization and ~10% at 6 dpf. The Wnt inhibitor LGK974 dose-dependently rescues both the shortened body length and cartilage malformation phenotypes at 0.05–0.1 μM — an important proof-of-concept for pathway-directed therapeutic targeting, though not yet translated to patients. 8. Tissue-level consequence: Defective chondrocyte elongation/intercalation within cartilage (e.g., Meckel's cartilage in zebrafish), producing disorganized chondrocyte stacking — the cellular basis of the profound skeletal growth failure and long-bone/vertebral dysplasia seen clinically. 9. Clinical manifestation: Severe prenatal-onset growth failure, skeletal dysplasia (clubfoot, brachytelephalangy, platyspondyly, coxa valga), and downstream complications (bone fragility, premature osteoarthritis, cervical stenosis).

Model discrepancy note (important knowledge gap): A C. elegans model of the orthologous cogc-4(av107) mutation (Kodera et al., PMID 33688625) failed to reproduce the Golgi phenotype:

"Our data suggest that this mutation in cogc-4(av107) worms does not lead to a detectable phenotype." ... "Normal ER and Golgi morphology and no evidence of co-localization was observed in our cogc-4(av107) early embryos."

This is best interpreted as a human/model mismatch — plausibly reflecting the worm ortholog's low (~29%) amino-acid identity with human COG4 rather than refuting the gain-of-function mechanism established independently in human fibroblasts and zebrafish.

Suggested GO terms: GO:0017119 (COG complex), GO:0006888 (ER-to-Golgi vesicle-mediated transport), GO:0006890 (retrograde vesicle-mediated transport, Golgi to ER), GO:0016477 (cell migration/convergent extension as relevant), GO:0016055 (Wnt signaling pathway), GO:0007368 (determination of left/right symmetry — not core), GO:0002062 (chondrocyte differentiation), GO:0030199 (collagen fibril organization). Suggested CL terms: CL:0000138 (chondrocyte), CL:0000057 (fibroblast). Suggested UBERON: UBERON:0002418 (cartilage tissue), UBERON:0000982 (Meckel's cartilage — zebrafish model), UBERON:0004537 (long bone). Suggested CHEBI: the Wnt inhibitor LGK974 (WNT974/CHEBI entry for the small molecule).

7. Anatomical Structures Affected

Organ/system level: - Skeletal system (primary): long bones, vertebrae (platyspondyly), hips (coxa valga), hands/feet (short distal phalanges, clubfoot), cranium (delayed fontanel closure, microcephaly with relative macrocephaly) - Ocular system: lens (cataracts), retina (rod-cone dystrophy, cystic macular changes), sclera (blue sclerae in infancy) - Auditory system: middle/inner ear (conductive, sensorineural, mixed hearing loss) - Hematologic system: neutrophil lineage (intermittent neutropenia) - Hepatic system: liver (elevated transaminases) - Nervous system (secondary/mechanical): cervical spinal cord (compression at the cranio-cervical junction due to skeletal stenosis, not a primary neurodevelopmental defect — cognition itself is spared) (PMID 35455576) - Craniofacial soft tissue: hair/eyebrow follicles (sparse), facial skeleton (micrognathia, nasal bridge)

Tissue/cell level: cartilage/growth plate chondrocytes (defective intercalation and elongation); dermal fibroblasts (the principal patient-derived cell type used in mechanistic studies, showing Golgi collapse); hepatocytes (transaminase elevation implies hepatocellular involvement, mechanism unestablished).

Subcellular level: the Golgi apparatus (GO Cellular Component: Golgi apparatus, GO:0005794; Golgi stack, GO:0005795) is the primary organelle affected — reduced volume, stack collapse, altered cis/trans compartmentalization; the endoplasmic reticulum secondarily, via the shifted anterograde/retrograde equilibrium.

Localization: Bilateral/symmetric skeletal involvement; cranio-cervical junction stenosis is midline/axial.

8. Temporal Development

Onset: Prenatal — growth restriction begins in utero and is measurable at birth (birth length/weight/OFC 2–2.4 SD below norms despite near-term delivery). Skeletal, ocular, and hearing findings emerge through infancy and early childhood (cataracts and neutropenia identified early; retinal dystrophy and premature osteoarthritis emerge later).

Progression: Progressive and lifelong, not self-limited. Height diverges further from population norms over childhood (final Z-scores of −4 to −8.5 SD, far below the birth Z-score of ~−2.3). Absolute head circumference becomes progressively microcephalic with age even as it remains relatively macrocephalic versus height. Hearing loss may progress over time. Premature degenerative joint disease and skeletal fragility emerge in the second-to-third decades. There is no described spontaneous remission of any core feature.

Disease course pattern: Chronic, non-relapsing, developmentally static in terms of cognition (normal and stable) but progressive in terms of skeletal/ocular/orthopedic morbidity.

Critical periods: The first months of life represent a critical growth-divergence window (sharp decline from population growth curves); early childhood is critical for cataract detection/surgery to prevent amblyopia; adolescence/gymnastics-type activity requires caution pending exclusion of atlantoaxial/cranio-cervical instability.

9. Inheritance and Population

Epidemiology. No formal prevalence or incidence estimate exists — Saul-Wilson syndrome is among the rarest characterized monogenic disorders, with ~14–16 molecularly confirmed individuals reported worldwide as of the principal cohort studies, plus scattered subsequent case reports (e.g., a 2026-published case from Saudi Arabia, PMC12883328, the first reported in that population, noting some novel facial features — triangular face, hypertelorism, plagiocephaly — alongside the classic gestalt).

Inheritance pattern: Autosomal dominant (HP:0000006), essentially always de novo.

Penetrance: Appears fully penetrant for the core skeletal/growth phenotype in all reported carriers (consistent with the small but uniform cohort).

Expressivity: Described as remarkably uniform/consistent across the cohort — an unusually tight phenotype for a dominant disorder, attributable to the single recurrent variant mechanism.

Genetic anticipation: Not applicable (not a repeat-expansion disorder).

Germline mosaicism: Documented in at least one family, informing empiric sibling recurrence-risk counseling above the general-population baseline despite the de novo origin in the proband.

Founder effects / consanguinity: Not relevant — dominant, recurrent de novo mechanism, not associated with consanguinity.

Carrier frequency: Not applicable (not a recessive carrier-screening condition).

Population demographics: Cases reported across multiple ancestries/geographies (US, Europe, and — most recently — Saudi Arabia), with no described ethnic or geographic clustering; sex ratio appears roughly even across reported cases (no strong male/female skew described in the literature reviewed).

10. Diagnostics

Clinical diagnosis is suggested by the combination of profound prenatal-onset short stature, the characteristic progeroid craniofacial gestalt, brachytelephalangy, and clubfoot, supported by skeletal radiographs (platyspondyly, long-bone overtubulation, coxa valga) — but is confirmed molecularly.

Molecular/genetic testing: - Targeted single-variant/single-gene testing for the recurrent COG4 c.1546G>A/C (p.Gly516Arg) change is the most efficient confirmatory test once SWS is clinically suspected, and detected 14/14 probands in the founding cohort. - Exome or genome sequencing is appropriate for undiagnosed/unrecognized presentations (this is in fact how the causal gene was originally identified, via the NIH Undiagnosed Diseases Network, ClinicalTrials.gov NCT02450851). - Chromosomal microarray/karyotype/FISH: not informative — SWS is not a copy-number or structural chromosomal disorder. - Gene-targeted deletion/duplication analysis: not expected to be useful, since the mechanism is a specific gain-of-function missense change, not haploinsufficiency.

Laboratory tests supporting diagnosis/monitoring: - CBC with differential (intermittent neutropenia — essentially universal finding, present in 12/12 tested) - Liver function tests (elevated transaminases in 6–8 of the cohort) - Serum N-/O-glycosylation studies are normal in SWS — useful specifically to distinguish SWS from classic COG4-CDG (whose hallmark is abnormal serum transferrin glycosylation), since the two conditions share the same gene but opposite functional mechanisms.

Imaging: Skeletal survey (platyspondyly, overtubulated long bones, coxa valga, brachytelephalangy); brain MRI (ventriculomegaly in ~56%); cranio-cervical spine MRI where clinically indicated (stenosis/myelopathy).

Ophthalmologic evaluation: Slit-lamp exam for lamellar cataracts; retinal exam/ERG for rod-cone dystrophy; OCT for cystic macular changes.

Audiologic evaluation: Baseline and serial audiometry given the mixed conductive/sensorineural/combined hearing-loss risk.

Differential diagnosis (from GeneReviews, NBK554080):

Disorder Distinguishing features from SWS
Silver-Russell syndrome Limb-length asymmetry, café-au-lait spots; lacks the skeletal dysplasia, ocular, and hearing findings of SWS
Osteogenesis imperfecta Dentinogenesis imperfecta typical; lacks SWS's distinctive dysplasia, cataracts, retinal degeneration
Microcephalic osteodysplastic primordial dwarfism type II (MOPD II) Vascular anomalies (e.g., cerebral aneurysms); no distal phalangeal shortening pattern of SWS
Wiedemann-Rautenstrauch syndrome Intellectual disability present (contrasts with SWS's normal cognition); lacks phalangeal shortening
Hallermann-Streiff syndrome More pronounced/distinct nasal and mandibular features
Floating-Harbor syndrome Distinctively different prominent-nose facial gestalt

Clinical diagnostic criteria: No formal consensus scoring system/society guideline exists (too rare); diagnosis rests on the gestalt + confirmatory molecular testing described above.

Screening: No population or newborn screening applicable given the de novo, non-carrier-based inheritance; once a familial variant is identified, prenatal testing and preimplantation genetic testing become available for future pregnancies in that family, with genetic counseling regarding residual sibling recurrence risk from possible germline mosaicism.

11. Outcome/Prognosis

Survival: No mortality data suggesting reduced lifespan have been reported; SWS is not typically fatal (unlike biallelic COG4-CDG, which is often lethal in infancy). Adults into their 20s–30s have been documented.

Growth outcome: Final adult height around 107–110 cm (roughly the stature of a typical 4–5-year-old), Z-scores of −4 to −8.5 SD — among the most severe short-stature phenotypes of any described skeletal dysplasia, unresponsive to growth hormone therapy.

Morbidity/complications: - Progressive hearing loss - Cataracts requiring surgery; risk of amblyopia if untreated; progressive rod-cone retinal dystrophy affecting night vision, sometimes to functional visual impairment - Premature/early-onset osteoarthritis, in documented adult cases requiring joint replacement surgery in the third decade of life - Bone fragility with fracture risk from minimal trauma - Cranio-cervical/atlantoaxial stenosis with myelopathy — a serious complication; a 2022 case report (PMID 35455576) documented decompressive surgery for critical cranio-cervical junction stenosis with cord compression, but found only limited radiological widening and no clinical or radiological improvement of the myelopathy postoperatively, "underscoring the surgical limitations imposed by the patient's severe skeletal dysplasia and soft bone characteristics" — an important prognostic caveat that surgical decompression may have limited efficacy in this population. - Persistent intermittent neutropenia into adulthood

Cognitive/functional outcome: Cognition remains normal throughout life — a favorable and distinguishing prognostic feature relative to many other severe skeletal dysplasias/primordial dwarfisms.

Prognostic factors: No validated prognostic biomarkers or scoring systems exist given the extremely small reported cohort; disease course appears remarkably uniform across patients given the single causal variant, so severity does not appear to vary meaningfully by genotype (all patients share the identical p.Gly516Arg change).

12. Treatment

There is no disease-modifying or curative therapy; management is multidisciplinary and supportive/symptomatic (GeneReviews NBK554080):

Pharmacotherapy: - Growth hormone: trialed in the cohort but statistically shown not to improve height (p = 0.052–0.489) — an important negative-evidence finding for clinical decision-making (NCIT:C15986 Pharmacotherapy; explicitly documented as ineffective). - G-CSF (granulocyte colony-stimulating factor): considered on a case-by-case basis if neutropenia is associated with frequent/severe infections (NCIT:C15986 Pharmacotherapy; therapeutic_agent candidate: filgrastim-class G-CSF).

Surgical/interventional: - Orthopedic surgery for clubfoot correction (NCIT:C16186 Orthopedic Surgical Procedure) - Cervical spine decompression surgery for cranio-cervical stenosis/myelopathy when present — though outcomes may be limited, as documented above (NCIT:C15329 Surgical Procedure) - Cataract surgery when lens opacity is visually significant, to prevent amblyopia (NCIT ophthalmologic surgical term) - Joint replacement surgery for premature osteoarthritis in adulthood (NCIT:C15329 / arthroplasty-specific term) - Myringotomy tube placement for conductive hearing loss

Supportive/rehabilitative: - Physical therapy / physiatry for mobility (NCIT:C15302 Physical Therapy) - Early intervention programs (ages 0–3) and developmental preschool (ages 3–5); speech and motor therapy (NCIT:C159273 Speech Therapy) - Individualized Education Program (IEP) services incorporating vision and hearing accommodations - Hearing aids as needed for hearing loss not addressed surgically - Night-vision aids and low-vision services for rod-cone dystrophy - Pain management for osteoarthritis (NCIT:C15747 Supportive Care)

Experimental/investigational — pathway-directed, preclinical only: The zebrafish model finding that the Wnt inhibitor LGK974 dose-dependently rescues both body-length and cartilage-malformation phenotypes (PMID 34595172) is a proof-of-concept for a targeted molecular therapy but has not been tested in SWS patients — no registered clinical trial for LGK974 or any other targeted SWS therapy was identified in this search. This represents the most promising translational lead in the current literature and a clear direction for future therapeutic development.

Genetic counseling (NCIT:C15240): recommended for families, addressing the near-universally de novo origin, the small but real germline-mosaicism-based sibling recurrence risk, and 50% transmission risk from an affected individual to offspring; prenatal and preimplantation genetic testing are available once the familial variant is confirmed.

Surveillance schedule (per GeneReviews):

System Recommended frequency
Growth/development Every visit
Musculoskeletal Annually; imaging per treating orthopedist
Eyes Annually
Hearing Annually
Cervical spine Per orthopedist/as clinically indicated
CBC/neutrophil count Annually

Precaution: Avoid gymnastics and trampoline use until atlantoaxial/cranio-cervical instability has been excluded, given the documented stenosis risk.

13. Prevention

Because Saul-Wilson syndrome arises from an essentially always de novo dominant variant with no known environmental trigger, there is no primary prevention strategy at the population level. The only actionable prevention lever is at the reproductive/family level: once a family's causal COG4 variant is molecularly confirmed (typically in an affected proband), prenatal diagnosis and preimplantation genetic testing (PGT) become available for subsequent pregnancies, informed by genetic counseling that accounts for the small residual recurrence risk from possible parental germline mosaicism. Secondary/tertiary prevention is essentially the surveillance and early-intervention program outlined in Section 12 (early cataract surgery to prevent amblyopia, cervical-spine monitoring to catch stenosis before myelopathy develops, hearing surveillance, neutropenia monitoring).

No vaccination, screening program, behavioral intervention, or public-health measure is applicable to this monogenic disorder.

14. Other Species / Natural Disease

No naturally occurring veterinary or wildlife cases of an orthologous COG4-gain-of-function disease have been reported. COG4 is broadly conserved (present with 29% amino-acid identity even in the distant C. elegans ortholog), but there is no OMIA entry or veterinary literature describing spontaneous Saul-Wilson-like disease in companion animals or livestock identified in this search. All animal data derive from engineered/induced models (zebrafish transgenic/knock-in of the human variant; C. elegans CRISPR-engineered orthologous mutation) rather than natural disease — see Section 15.

15. Model Organisms

Zebrafish (Danio rerio) — the primary and most informative in vivo model: - Model: transgenic/mosaic expression of human COG4^p.G516R^ (Ng et al., Dis Model Mech 2021, PMID 34595172, "A Dominant Heterozygous Mutation in COG4 Causes Saul-Wilson Syndrome, a Primordial Dwarfism, and Disrupts Zebrafish Development via Wnt Signaling") - Phenotype recapitulation — good: convergent-extension defects during gastrulation, shortened body length (~18% reduction at 3 dpf, ~10% at 6 dpf), malformed jaw (Meckel's) cartilage with abnormal chondrocyte intercalation/stacking, and glypican accumulation — closely mirroring the human skeletal dysplasia and the glypican-accumulation biochemistry seen in patient fibroblasts. - Mechanistic utility: enabled discovery of the causal role of elevated wnt4 transcripts (overexpression alone phenocopies the defect) and served as an in vivo pharmacologic rescue platform — the Wnt inhibitor LGK974 rescued both body-length and cartilage phenotypes in a dose-dependent manner (0.05–0.1 μM). - A related COG4-CDG zebrafish model has also been reported, with both COG4-CDG and COG4-SWS zebrafish models displaying small body length, abnormal pectoral fins, and abnormal chondrocyte stacking — useful for comparative gain- vs loss-of-function studies.

Human patient-derived fibroblasts (primary cell model): the principal cellular system used across multiple studies (Ferreira et al. 2018; Xia et al. 2022) to establish the Golgi-collapse, trafficking-kinetics, and proteoglycan-glycosylation phenotypes; considered high-fidelity since it is the actual patient genotype in the actual patient cell type, though fibroblasts are not the primary disease-relevant tissue (cartilage/bone).

Chondrocyte-like cell models (in vitro, induced): COG4^p.G516R^ knock-in chondrocyte-like cell lines used for 3D spheroid chondrogenesis assays (Xia et al. 2022, PMID 36393834) — recapitulate impaired chondrogenic differentiation (reduced MMP13/COL10A1, blunted BMP2 response, smaller spheroids, increased apoptosis) and demonstrated non-cell-autonomous rescue by wild-type conditioned medium, directly implicating a missing secreted paracrine factor as pathogenic — a mechanistically important and translationally relevant model limitation/insight (i.e., the defect may be extrinsically rescuable).

C. elegans model — a documented human/model mismatch: - Model: CRISPR-engineered cogc-4(av107) orthologous mutation (Kodera et al. 2021, PMID 33688625, "Saul-Wilson Syndrome Missense Allele Does Not Show Obvious Golgi Defects in a C. elegans Model") - Fails to recapitulate: normal ER/Golgi morphology, no detectable phenotype in early embryos — in contrast to the clear Golgi collapse seen in human fibroblasts and the developmental phenotype in zebrafish. - Interpretation: likely reflects the C. elegans ortholog's limited (~29%) sequence conservation with human COG4 rather than refuting the human gain-of-function mechanism; a clear candidate for a HUMAN_MODEL_MISMATCH-type knowledge-gap annotation, since evidence exists in this model system but its translational validity to human/vertebrate biology is explicitly limited by low ortholog conservation.

Applications: the zebrafish LGK974-rescue result is the field's clearest current lead for translational/therapeutic research; fibroblast and chondrocyte models remain the standard platforms for mechanistic dissection of the trafficking and secretome defects.

Summary of Key Citations

PMID/ID Citation Contribution
30290151 Ferreira CR et al., Am J Hum Genet 2018;103(4):553-567 Molecular discovery: recurrent COG4 p.G516R, gain-of-function trafficking/Golgi mechanism
(GIM 2020) Ferreira CR et al., Genet Med 2020;22(5):857-866, "Defining the clinical phenotype of Saul-Wilson syndrome" Comprehensive clinical phenotyping, n=14–16 cohort
32652690 Ferreira CR et al., Am J Med Genet A 2020, "Growth in individuals with Saul-Wilson syndrome" Detailed growth curves, GH non-response, relative macrocephaly
34595172 Ng BG et al., Dis Model Mech 2021, zebrafish Wnt signaling paper Zebrafish model, wnt4/glypican mechanism, LGK974 rescue
36393834 Xia ZJ et al., Front Cell Dev Biol 2022;10:979096 Chondrocyte secretome, MMP13/IGFBP7, non-cell-autonomous rescue
33688625 Kodera et al., 2021 C. elegans model — negative/mismatch result
35455576 Case report, Childs Nerv Syst 2022 Cranio-cervical stenosis complication and limited surgical outcome
30548960 Commentary, 2018 Historical framing, "early days until now"
GeneReviews NBK554080 Ferreira, Lee, Huang Comprehensive management/surveillance/differential-diagnosis reference

Note on evidence gaps: No dedicated GWAS, population prevalence study, disease registry, dedicated QoL instrument study, or registered clinical trial for a targeted therapy was located. The Wnt-inhibitor rescue in zebrafish (LGK974) is the field's clearest translational lead but remains preclinical.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 13
Resolved 13
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 13
On topic 10
Off topic 0

All extracted references resolved successfully.